Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
The French navy intercepted the Russian tanker GRINCH in the Western Mediterranean, an operation supported by multiple allied navies including the UK. The vessel is suspected of evading sanctions by operating within a shadow fleet that facilitates Russia's oil exports despite European Union restrictions. This enforcement action emphasizes ongoing i…
Piper Sandler has upgraded Elanco Animal Health to an Overweight rating, highlighting the company's enhanced presence within large veterinary corporate groups and strong product prospects. The price target for Elanco has been raised to $30. Conversely, Zoetis has been downgraded to Neutral due to anticipated innovation slowdowns and revised price t…
Thursday's trading session exhibited pronounced fluctuations across a spectrum of stocks. Major companies such as Alibaba and Facebook experienced notable gains, while others like Abbott Laboratories faced declines. The movements reflect a complex interplay of earnings reports, corporate developments, and strategic announcements affecting various m…
The Istanbul Stock Exchange's main benchmark, the BIST 100, finished Thursday's session with a 0.97% increase, reaching an all-time high. Gains were primarily driven by strong performances in Telecoms, Textile & Leather, and Information Technology sectors. Key individual stocks, including Katilimevim Tasarruf Finansman AS and EIS Eczacibasi Ilac Si…
Stifel has raised its price target on Revolution Medicines (NASDAQ: RVMD) substantially to $170 from $85, underscoring strong confidence in the biotech firm's long-term revenue prospects and pipeline value. This new valuation indicates significant upside from the current share price, reflecting increased M&A interest and promising clinical data, de…
UBS has reiterated its Buy recommendation for ResMed with a price target of $345, highlighting the company's sustained strength in the U.S. market and expected improvements in international sales. ResMed’s recent financial results surpassed revenue forecasts, although some analysts expressed caution due to competitive pressures and potential impact…
UBS has upheld its Neutral rating and $290 price target on Travelers following the insurer's impressive fourth-quarter earnings that surpassed expectations. Although the company demonstrated significant earnings and revenue beats, UBS emphasized concerns over subdued premium growth and slowing renewal rates in the Business Insurance segment, which …
UBS raised its price target for Charles Schwab to $125, maintaining a Buy rating, in the wake of the company's Q4 performance and confident 2026 outlook. The upward revision reflects solid earnings, revenue growth, and strong core business metrics, with other analysts similarly optimistic on Schwab's future prospects amid stable shareholder returns…
UBS reaffirmed its Buy rating on Coterra Energy, assigning a price target of $33. The firm projects operational enhancements by late 2025, buoyed by robust revenue growth and potential expansions in share repurchases. Investor focus remains on activist influences and possible M&A actions, while dividend stability and financial health contribute pos…
UBS has increased its price target for United Airlines to $147 from $145 after the airline reported better-than-expected fourth-quarter results. The company’s forward guidance for the upcoming quarter and 2026 aligns with investor anticipations, while analysts remain optimistic about potential earnings upgrades. Despite a current trading price of $…
Senior health insurance executives from prominent U.S. companies testified before Congressional committees, addressing soaring healthcare costs and worsening affordability for American consumers. The hearings come amid significant premium increases under the Affordable Care Act and after the cessation of enhanced COVID-related subsidies. Rising emp…
Officials from leading health insurance firms—including CVS Health, Cigna, UnitedHealth, and Elevance—testified before U.S. congressional committees regarding escalating healthcare expenses and the consequent decline in affordability for Americans. This scrutiny arises as consumers confront significantly higher Obamacare premiums after the cessatio…
Commercial Metals Company director Dennis V. Arriola has increased his stake in the company by acquiring 2,000 shares at $74.69 each, totaling $149,380. This move comes as the company reported first-quarter fiscal 2026 results that surpassed analyst expectations on both earnings and revenue. Subsequently, Jefferies raised its price target for the s…
Freeport-McMoRan Inc. is actively pursuing the restoration of its Grasberg mine following a recent operational setback, with goals to recover most of its output by the latter half of the year. The company also projects significant increases in copper production from its leach operations and expanded output in the U.S., while navigating evolving mar…
The hedge fund industry witnessed unprecedented growth in 2023, with net inflows hitting a 16-year high and total assets surpassing the $5 trillion milestone. Improved returns and market volatility led to this surge, positioning hedge funds as a preferred vehicle for portfolio diversification amid evolving economic conditions.
In 2023, hedge funds experienced their strongest capital inflows since before the 2008 financial crisis, with investor net contributions reaching approximately $116 billion. Performance gains further accelerated asset expansion, pushing total hedge fund industry assets beyond a historic milestone of $5 trillion. This surge in interest reflects robu…
UBS has reaffirmed its Buy recommendation and $93 price target for Colgate-Palmolive, citing confidence in the company’s growth potential and stable financial position despite minor recent revenue declines. The company's valuation at a premium compared to peers reflects strong fundamentals and investor optimism around organic growth prospects and d…
UBS has maintained its Buy rating for Home Depot, setting a $430 price target, driven by optimism that the company is well-positioned to benefit from a future market recovery in home improvement. Despite uncertainties surrounding the timing of demand rebound, Home Depot's focus on controllable factors underpins its cautious but confident outlook. C…
Truist Securities has raised its price target for TE Connectivity to $244 from $240, maintaining a Hold rating. While TE Connectivity's latest quarterly results were solid, a slowdown in the Chinese electric vehicle market has impacted guidance for early 2026. Gains in industrial sectors, including data center AI and energy, have helped mitigate co…
UBS reaffirmed its Neutral rating and $92 price target for Church & Dwight as the company prepares to release its fourth-quarter 2025 earnings. Anticipated earnings per share slightly exceed consensus and guidance, but industry headwinds and product divestitures are expected to temper upside potential. Other firms have issued mixed upgrades, reflec…
DA Davidson has reduced its price target for CommVault Systems to $185 from $220, reflecting a broad software industry selloff and compressed peer valuation multiples. Despite this revision, the firm upholds a Buy rating and anticipates strong fiscal third-quarter 2026 results, highlighting the company's solid revenue growth and gross margins. Peer…
Truist Securities has raised its price target for Charles Schwab Corp. to $122 from $120, maintaining a Buy rating. The adjustment reflects stronger net interest income projections and revenue growth anticipated beyond company guidance. Other firms have also lifted targets following solid fourth-quarter results and optimistic future projections.
Halliburton's latest quarterly earnings surpassed analysts' estimates, leading UBS to maintain a Neutral rating with a $32 price target. The oilfield services company exhibited robust revenue and earnings growth, yet modest profit margins and sector-specific headwinds temper the outlook. Analysts highlight a potential upturn in U.S. fracking activi…
DA Davidson has revised upward its price target for SS&C Technologies Holdings, Inc. to $106 from $102, maintaining a Buy rating as the company prepares to release its fourth-quarter 2025 earnings. The financial technology firm is expected to report steady revenue growth supported by recent acquisitions and organic expansion, with initial 2026 guid…
UBS has reaffirmed its Buy rating and $28.50 price target on Smithfield Foods after the company announced an all-cash deal to acquire Nathan’s Famous for around $450 million. The transaction aligns with Smithfield's targeted expansion in the Packaged Meats sector, supported by a stable financial framework and expected cost synergies. The acquisitio…
